Substance / Medication

Olanzapine

Overview

Active Ingredient
olanzapine
RxNorm CUI
61381
Labeler: Eugia US LLCUpdated: 2026-02-17T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Warnings and Precautions (5.1) Use in Specific Populations (8.5) Patient Counseling Information (17) [see,, and] Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10

Contraindications

When this intervention should not be used

None with olanzapine monotherapy. For specific information about the contraindications of lithium or valproate, refer to the Contraindications section of the package inserts for these other products.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
The effect of olanzapine on lipid profiles in humans: a time and dose response meta-analysis of randomized controlled trials.
Fang Zhou, Jamilian Parmida, Safargar Mohammad et al. · BMC Cardiovasc Disord · 2026
PMID: 41491797Meta-Analysis
Olanzapine for the Prevention of Postoperative Nausea and Vomiting: An Updated Meta-Analysis With Trial Sequential Analysis.
Hussein Ayham Mohammad, Yasin Jehad A, Aldalati Abdullah Yousef et al. · J Pain Symptom Manage · 2025
PMID: 39952307Meta-Analysis
Olanzapine/Samidorphan Effects on Weight Gain: An Individual Patient Data Meta-Analysis of Phase 2 and 3 Randomized Double-Blind Studies.
Correll Christoph U, Doane Michael J, McDonnell David et al. · J Clin Psychiatry · 2025
PMID: 39832309Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Olanzapine (substance)
SNOMED CT
386849001
UMLS CUI
C0171023
RxNorm CUI
61381
Labeler
Eugia US LLC

Clinical Data

This intervention maps to 9 entities in the Healos knowledge graph.

4
Conditions
3
Biomarkers
1
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.